Cost-Effectiveness of Oseltamivir Treatment for Children with Uncomplicated Seasonal Influenza

Objective To evaluate the cost-effectiveness of oseltamivir treatment for seasonal influenza in children and consider the impact of oseltamivir resistance on these findings. Study design We developed a model to evaluate 1-year clinical and economic outcomes associated with 3 outpatient management st...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of pediatrics Vol. 160; no. 1; pp. 67 - 73.e6
Main Authors Lavelle, Tara A., MS, Uyeki, Timothy M., MD, MPH, MPP, Prosser, Lisa A., PhD
Format Journal Article
LanguageEnglish
Published Maryland Heights, MO Elsevier Inc 2012
Mosby, Inc
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective To evaluate the cost-effectiveness of oseltamivir treatment for seasonal influenza in children and consider the impact of oseltamivir resistance on these findings. Study design We developed a model to evaluate 1-year clinical and economic outcomes associated with 3 outpatient management strategies for unvaccinated children with influenza-like-illness: no antiviral treatment; diagnostic testing and oseltamivir treatment when positive; and empiric oseltamivir treatment. The model depicted a hypothetical non-pandemic influenza season with a 29% level of oseltamivir resistance in circulating viruses, and 14% to 54% probability of seasonal influenza with influenza-like-illness. Strategies were compared with incremental cost-effectiveness ratios. Results In our primary analysis, empiric oseltamivir treatment consistently produced the greatest benefit. The incremental cost-effectiveness of this alternative, compared with testing and treating, was <$100 000 per quality-adjusted life year gained in all age groups except the oldest. The testing strategy was consistently more effective compared with no treatment and cost between $25 900 and $71 200 per quality-adjusted life year gained, depending on age. Results were sensitive to the prevalence of oseltamivir resistance in circulating viruses. Conclusion Empiric oseltamivir treatment of seasonal influenza is associated with favorable cost-effectiveness ratios, particularly in children aged 1 to <12 years, but ratios are highly dependent on the prevalence of oseltamivir resistance among circulating influenza viruses.
Bibliography:http://dx.doi.org/10.1016/j.jpeds.2011.07.001
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-3476
1097-6833
DOI:10.1016/j.jpeds.2011.07.001